# 1 Exploring the ATN classification system using Brain Morphology

Nils Heinzinger<sup>1,2</sup>, Anne Maass<sup>1,2</sup>, David Berron<sup>1,2</sup>, Renat Yakupov<sup>1,2</sup>, Oliver Peters<sup>3,4</sup>, 2 Jochen Fiebach<sup>29</sup>, Kersten Villringer<sup>29</sup>, Lukas Preis<sup>4</sup>, Josef Priller<sup>3,5,27,28</sup>, Eike Jacob 3 Spruth<sup>3,5</sup>. Slawek Altenstein<sup>3,5</sup>, Anja Schneider<sup>6,7</sup>, Klaus Fliessbach<sup>6,7</sup>, Jens 4 Wiltfang<sup>9,10,25</sup>, Claudia Bartels<sup>10</sup>, Frank Jessen<sup>6,11,24</sup>, Franziska Maier<sup>11</sup>, Wenzel Glanz<sup>1</sup>, 5 Buerger<sup>12,13</sup>. Janowitz<sup>13</sup>, Dichgans<sup>12,13</sup>. 6 Katharina Daniel Martin Robert Perneczky<sup>12,18,19,20</sup>, Boris-Stephan Rauchmann<sup>18</sup>, Stefan Teipel<sup>14,15</sup>, Ingo Killimann<sup>14,15</sup>, 7 Doreen Göerß<sup>15</sup>, Christoph Laske<sup>16,17</sup>, Matthias H. Munk<sup>16,17</sup>, Annika Spottke<sup>6,8</sup>, Nina 8 9 Roy<sup>6</sup>, Michael T. Heneka<sup>6,7</sup>, Frederic Brosseron<sup>6,7</sup>, Laura Dobisch<sup>1</sup>, Michael Ewers<sup>12</sup>, Peter Dechent<sup>21</sup>, John Dylan Haynes<sup>22</sup>, Klaus Scheffler<sup>23</sup>, Steffen Wolfsgruber<sup>6,7</sup>, Luca 10 Kleineidam<sup>6</sup>, Matthias Schmid<sup>6,26</sup>, Moritz Berger<sup>26</sup>, Emrah Düzel<sup>1,2,\*</sup>, Gabriel Ziegler<sup>1,2,\*</sup> 11

12 \* Shared last-authorship, <sup>1</sup> German Center for Neurodegenerative Diseases (DZNE), Magdeburg, 13 Germany, <sup>2</sup> Institute of Cognitive Neurology and Dementia Research (IKND), Otto-von-Guericke University, Magdeburg, Germany, <sup>3</sup> German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany, <sup>4</sup> 14 15 Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Department of Psychiatry, Berlin, Germany, <sup>5</sup> Department of Psychiatry and Psychotherapy, Charité, Berlin, Germany, <sup>6</sup> German Center for 16 17 Neurodegenerative Diseases (DZNE), Bonn, Germany, <sup>7</sup> University of Bonn Medical Center, Dept. of 18 Neurodegenerative Diseases and Geriatric Psychiatry/Psychiatry, Bonn, Germany, <sup>8</sup> Department of 19 Neurology, University of Bonn, Bonn, Germany, <sup>9</sup> German Center for Neurodegenerative Diseases (DZNE), 20 Göttingen, Germany, <sup>10</sup> Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, 21 University of Göttingen, Göttingen, Germany, <sup>11</sup> Department of Psychiatry, University of Cologne, Medical 22 Faculty, Cologne, Germany, <sup>12</sup> German Center for Neurodegenerative Diseases (DZNE), Munich, 23 Germany, <sup>13</sup> Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, 24 Germany, <sup>14</sup> German Center for Neurodegenerative Diseases (DZNE), Rostock, Germany, <sup>15</sup> Department 25 of Psychosomatic Medicine, Rostock University Medical Center, Rostock, Germany, <sup>16</sup> German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany, <sup>17</sup> Section for Dementia Research, Hertie 26 27 Institute for Clinical Brain Research and Department of Psychiatry and Psychotherapy, University of NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Tübingen, Tübingen, Germany, <sup>18</sup> Department of Psychiatry and Psychotherapy, University Hospital, LMU 28 29 Munich, Munich, Germany, <sup>19</sup> Munich Cluster for Systems Neurology (SyNergy), Munich, Germany, <sup>20</sup> Ageing Epidemiology Research Unit (AGE), School of Public Health, Imperial College London, London, 30 31 UK, <sup>21</sup> MR-Research in Neurosciences, Department of Cognitive Neurology, Georg-August-University 32 Göttingen, Germany, <sup>22</sup> Bernstein Center for Computational Neuroscience, Charité-Universitätsmedizin, 33 Berlin, Germany, <sup>23</sup> Department for Biomedical Magnetic Resonance, University of Tübingen, Tübingen, 34 Germany, <sup>24</sup> Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany, <sup>25</sup> Neurosciences and Signaling Group, Institute of Biomedicine 35 (iBiMED), Department of Medical Sciences, University of Aveiro, Aveiro, Portugal, <sup>26</sup> Institute for Medical 36 37 Biometry, University Hospital Bonn, Bonn, Germany, 27 School of Medicine, Technical University of Munich, Department of Psychiatry and Psychotherapy, Munich, Germany, <sup>28</sup> University of Edinburgh and UK DRI, 38 39 Edinburgh, UK, <sup>29</sup> Center for Stroke Research Berlin, Charité-Universitätsmedizin, Berlin, Germany

40

(c) Correspondence to: Nils Heinzinger; Institute for Cognitive Neurology and Dementia
Research; University Hospital Magdeburg, University of Magdeburg, Leipziger Str. 44,
39120 Magdeburg, Germany; Email: nils.heinzinger@st.ovgu.de

44

- 45 Alzheimer's Research & Therapy keywords: MRI, Alzheimer's disease, memory, Voxel-
- 46 based Morphometry, VBM, ATN, biomarker, Amyloid

- 48 Word count for paper: 6056
- 49 Word count for abstract: 350
- 50 Character count for title: 62
- 51 Number of references: 80
- 52 Number of tables: 3

- 53 Number of figures: 6
- 54 Supplementary data:
- 55 Number of tables: 2
- 56 Number of figures: 4

## 71 Abstract

Background: The NIA-AA proposed Amyloid-Tau-Neurodegeneration (ATN) as a classification system for AD biomarkers. The Amyloid Cascade Hypothesis (ACH) implies a sequence across ATN groups that patients might undergo during transition from healthy towards AD: A-T-N- $\rightarrow$ A+T-N- $\rightarrow$ A+T+N+. Here we assess the evidence for monotonic brain volume decline for this particular (Amyloid-conversion first, Tauconversion second, N-conversion last) and alternative progressions using Voxel-based Morphometry (VBM) in a large cross-sectional MRI cohort.

Methods: We used baseline data of the DELCODE cohort of 437 subjects (127 Controls, 79 168 SCD, 87 MCI, 55 AD patients) which underwent lumbar puncture, MRI scanning and 80 neuropsychological assessment. ATN classification was performed using CSF-81 AB42/AB40 (A+/-), CSF-phospho-Tau (T+/-), and adjusted hippocampal volume or CSF-82 total-Tau (N+/-). We compared voxel-wise model evidence for monotonic decline of gray 83 84 matter volume across various sequences over ATN groups using the Bayesian 85 Information Criterion (including also ROIs of Braak stages). First, face validity of the ACH transition sequence A-T-N- $\rightarrow$ A+T-N- $\rightarrow$ A+T+N- $\rightarrow$ A+T+N+ was compared against 86 87 biologically less plausible (permuted) sequences among AD-continuum ATN groups. Second, we evaluated evidence for 6 monotonic brain volume progressions from A-T-N-88 towards A+T+N+ including also non-AD-continuum ATN groups. 89

90 **Results:** The ACH-based progression A-T-N-→A+T-N-→A+T+N-→A+T+N+ was 91 consistent with cognitive decline and clinical diagnosis. Using hippocampal volume for 92 operationalization of neurodegeneration (N), ACH was most evident in 9% of gray matter 93 predominantly in the medial temporal lobe. Many cortical regions suggested alternative 94 non-monotonic volume progressions over ACH progression groups, which is compatible

95	with an early amyloid-related tissue expansion or sampling effects e.g. due to brain-
96	reserve. Volume decline in 65% of gray matter was consistent with a progression where
97	A status converts before T or N status (i.e. ACH/ANT) when compared to alternative
98	sequences (TAN/TNA/NAT/NTA). Brain regions earlier affected by Tau tangle deposition
99	(Braak stage I-IV, MTL, limbic system) present stronger evidence for volume decline than
100	late Braak-stage ROIs (V/VI, cortical regions). Similar findings were observed when using
101	CSF-total-Tau for N instead.
102	Conclusion: Using the ATN classification system, early Amyloid status conversion
103	(before Tau and Neurodegeneration) is associated with brain volume loss observed
104	during AD progression. The ATN system and the ACH are compatible with monotonic
105	progression of MTL atrophy.
106	DRKS00007966, 04/05/2015, retrospectively registered
107	
108	
109	
110	
111	
112	
113	

# 117 Introduction

Alzheimer's disease (AD) is a slowly evolving neurodegenerative condition where initial
 brain changes can be found up to decades before the clinical onset and ultimately result
 in progredient cognitive decline and brain atrophy often studied with Magnetic Resonance
 Imaging (MRI)<sup>1-3</sup>.

122 AD is characterized by the accumulation of protein deposits, i.e. β-Amyloid plagues and neurofibrillary tangles (NFT) consisting of hyperphosphorylated Tau which can be 123 assessed using cerebrospinal fluid (CSF) biomarkers<sup>4,5</sup>. A reliable marker reflecting 124 Amyloid deposition is the Aβ42/Aβ40 ratio which decreases with increasing deposition<sup>6</sup>. 125 Accumulation of Tau tangles is mirrored by increasing CSF hyperphosphorylated Tau, 126 while CSF total Tau has been more generally associated with neuronal loss, not 127 necessarily AD specific. Those biomarkers have shown potential for predicting the clinical 128 diagnostic conversions<sup>7-9</sup> and worsening of memory performance during disease 129 progression<sup>10</sup>. 130

One key concept about the disease progress and pathological timeline has been 131 introduced as the Amyloid Cascade Hypothesis (ACH)<sup>11-13,1</sup>. Due to different 132 predispositions, including age<sup>14</sup>, genes<sup>15</sup> or vascular risk factors<sup>16</sup>, ß-Amyloid is 133 increasingly formed from precursor proteins which leads to its aggregation in the brain. 134 135 Then, ß-Amyloid can induce hyperphosphorylation and malformation/misfolding of intracellular Tau proteins, which aggregate in forms of NFTs<sup>13</sup>. Increased cellular stress 136 results in neuronal loss which typically manifests behaviourally in progressive cognitive 137 decline. Neuronal death in AD manifests in a typical MRI atrophy pattern with strongest 138 morphometrical changes situated in medial temporal lobe (MTL) and other limbic regions, 139 while the primary motor and sensory cortex are often spared<sup>17,18</sup>. Although the ACH was 140

postulated about 30 years ago, the hypothesis is still under refinement and critical review<sup>13,19,20</sup>. Moreover, the stereotypical progression pattern of Tau/NFT spread from the transentorhinal region via the limbic system to the whole cortex during AD progression can be classified into six Braak stages, which have been first described in an autopsy study<sup>5</sup>, and later tested in positron emission tomography studies<sup>21,22</sup> or VBM atrophy studies<sup>23</sup>.

147 Recently, a new descriptive ATN classification for AD which emphasises pathological and physiological rather than traditional clinical measures such as neuropsychological test 148 scores was proposed<sup>24,25</sup>. In the ATN system, for the three binary categories Amyloid 149 150 burden, Tau burden and Neurodegeneration, subjects are rated as normal (physiological, "-") or abnormal (pathological, "+"). The resulting 8 ( $=2^3$ ) groups with different biomarker 151 combinations range from A-T-N- (suggesting no pathology) to A+T+N+ (with pathology in 152 all categories). It has been suggested that all ATN biomarker combinations with A+ reflect 153 a pathological change related to the AD continuum. Several recent studies explored the 154 155 prognostic possibilities for clinical progression and cognitive decline using ATN<sup>26-30</sup>. However, while the ATN classification does not directly imply a progression cascade or a 156 set of subsequently following stages per se, it may be used for this particular purpose. 157 For example, the sequence of a disease transition across pathology groups (1) A-T-N-158 (2) A+T-N- (3) A+T+N- (4) A+T+N+ is more compatible with the amyloid cascade 159 hypothesis than other progression sequences based on ATN classification groups<sup>25</sup>. If 160 individual participants follow this particular disease progression profile, this would imply 161 a monotonic volume loss across groups  $(1) \rightarrow (2) \rightarrow (3) \rightarrow (4)$  in brain areas associated with 162 AD. While above progression sequence is partially supported in selected studies<sup>31,32</sup>, 163 those findings are limited to recordings of non-imaging between-group biomarker 164 differences. Although there is evidence for deviating sequences of progression<sup>32</sup>, studies 165

focusing on local voxel-based anatomical analysis in relation to ATN groups are still
 missing (see eg.<sup>33</sup>).

Here we study whether above progression implied by the ACH is reflected in specific patterns of local GM volume decline using cross-sectional data from a large neuroimaging cohort (DELCODE; DZNE Longitudinal Cognitive Impairment and Dementia Study) which is well characterized by CSF biomarkers. The DELCODE cohort is specifically enriched in subjects that are at risk for developing AD such as Subjective Cognitive Decline (SCD), but also Mild Cognitive Impairment (MCI) and thus more likely comprises individuals in early preclinical stages of AD (A+).

GM volume is a sensitive marker for local brain changes or pathological processes. As 175 this marker is continuous, smallest substance differences for all brain regions can be 176 measured and intermediate changes are detectable even when they would not cause an 177 ATN status conversion. We hypothesize that GM in the hippocampal-network decreases 178 179 following the ACH sequence and (1) test face validity of an ACH-based sequence using Voxel-based Morphometry without *a-priori* regional assumptions; and (2) compare the 180 evidence for volume loss reflecting the ACH sequence in comparison to other biologically 181 182 possible progressions outside the AD continuum. Finally, the concordance between ACH progress and Braak staging is evaluated. We expect earlier Braak stages to be stronger 183 affected by atrophy during the ACH sequence. It might occur that the volume alteration is 184 regionally modulated by e.g. reserve mechanisms. Since operationalization might be 185 crucial, we also evaluate the impact of alternative choices for dichotomization of the N 186 category using both t-Tau or hippocampal volume. 187

188

#### 189 Methods

#### 190 Study Design and Participants

This study uses the baseline data of the DELCODE cohort, an observational multicentre 191 study with 10 sites from the German Centre of Neurodegenerative Diseases (DZNE). Its 192 193 focus is the multimodal assessment of preclinical stages of dementia of Alzheimer's type (DAT) including SCD, MCI, DAT, and DAT relatives<sup>34</sup>. While SCD, MCI and DAT 194 participants were recruited from memory clinics, relatives of DAT patients and healthy 195 controls were recruited by advertisement and initially screened per phone for self-196 experienced cognitive decline and memory worries. Further SCD inclusion criteria were 197 a normal cognitive performance (specified as within 1.5 SD compared to an age, sex and 198 education years adjusted control group) in all subtests of the CERAD-plus battery and a 199 MMSE score between 26 and 30 and a CDR score <= 0.5. 200

Participants with MCI were below 1.5 SD in the CERAD-plus battery, but did not fulfil dementia criteria of NINDCS/ADRDA<sup>35</sup>. Subjects diagnosed as DAT were fulfilling NINDCS/ADRDA criteria, have a CERAD-plus score of below 1.5 SD, and were within an extended MMSE score range of 18-26 and have a CDR rating of >= 1. DAT relatives have a first-grade sibling with diagnosed DAT and do not fulfil MCI or DAT criteria.

Noncomplaining healthy controls (NC) neither suffered from subjective or objective 206 cognitive impairment. All participants were native German speakers, older than 60 years, 207 and gave written informed consent and had a study partner available for consultation. 208 Other neurological or psychiatric disorders than DAT were excluded. More information on 209 study design and inclusion/exclusion criteria can be found elsewhere<sup>34</sup>. DELCODE is 210 retrospectively registered at the German Clinical Trials Register (DRKS00007966), 211 (04/05/2015) and was approved by ethical committees and local review boards. Of a total 212 of 1079 participants at baseline timepoint, we finally included 437 subjects with available 213

quality checked MRI imaging and CSF biomarkers (see below). Based on a clinical
classification approach, this includes 127 NC (including DAT relatives), 168 SCD, 87 MCI
and 55 DAT patients. A summary of demographic information of the analysed sample is
provided in results table 1.

## 218 Neuropsychological testing

In DELCODE, subjects underwent a large battery of neuropsychological tests. Due to our
 focus on global cognition and memory aspects in healthy and (pre-) clinical DAT patients,
 we use the Mini Mental State Examination (MMSE, <sup>36</sup>) and a reliable memory composite
 factor score (further denoted as memory performance). This score was created by
 Confirmatory Factor Analysis and enables detecting subtle cognitive deviations in SCD
 when compared to NC subjects<sup>37</sup>.

#### 225 Biomarker and MRI data acquisition

Lumbar puncture was carried out by trained study assistants in 49% of DELCODE participants. CSF samples were centrifuged, aliquoted and stored at -80°C for retests. Biomarkers known to be related to AD pathology (CSF Aβ42, Total Tau, hyperphosphorylated Tau) were determined by commercially available kits (V-PLEX Aβ Peptide Panel 1 (6E10) Kit (K15200E), V-PLEX Human Total Tau Kit (K151LAE) (both Mesoscale Diagnostics LLC, Rockville, USA), Innotest Phospho-Tau(181P) (81581; Fujirebio Germany GmbH, Hannover, Germany)).

MRI scans were acquired in 9 out of 10 involved DZNE sites (3T Siemens scanners: 3
TIM Trio systems, 4 Verio systems, 1 Skyra and 1 Prisma system). Our main analyses
were based on whole brain T1-weighted MPRAGE (3D GRAPPA PAT 2, 1 mm<sup>3</sup> isotropic,
256 X 256 px, 192 slices, sagittal, ~5 min, TR 2500 ms, TE 4.33 ms, TI 110 ms, FA 7°).
Further ROI and covariate processing was based on additionally available FLAIR and T2-

weighted protocols (for details see<sup>34</sup>). Additional details on standard operation
 procedures, quality assurance and assessment (QA), performed by the DZNE imaging
 network (iNET, Magdeburg), can be found elsewhere<sup>34</sup>.

#### 241 Image processing and computational brain morphometry

The MPRAGE images were processed using SPM (SPM12 v7771, Statistical Parametric 242 Mapping software; Wellcome Trust Centre for Human Neuroimaging, London, UK, <sup>38</sup>) and 243 CAT-Toolbox (CAT12.6 r1450, Structural Brain Mapping group, Jena University Hospital, 244 Jena, Germany, <sup>39</sup>) under MATLAB (r2019b, The MathWorks, Inc., Natick, 245 246 Massachusetts, USA). As first step, a correction for field inhomogeneities was applied. Then the images were segmented into GM, WM and CSF maps using CAT which includes 247 a partial volume estimation correction on AMAP approach<sup>40</sup>. The received tissue maps 248 with a 1 mm isometric voxel size are warped to a study-specific template in MNI space 249 using Geodesic Shooting approach<sup>41</sup>. The GM tissue maps were modulated by the 250 251 jacobian determinant to enable voxel-based comparisons of local gray matter volume across subjects. A Gaussian blurring kernel was applied with 6 mm full width half 252 maximum (FWHM). The resulting tissue maps were quality tested using CAT's sample 253 homogeneity check and 15 subjects were excluded due to preprocessing artifacts. 254

For complementary ROI analysis we used Freesurfer's (v6.0, <sup>42</sup>) volume reconstruction (cortical stream<sup>43</sup>, subcortical stream<sup>44</sup>) to extract region of interest volumes. This was carried out by the default pipeline initiated by a 'recon-all -all' command which contains all preprocessing steps needed, including for example intensity normalization, surface registration to Talairach space, skull stripping, subcortical segmentation and calculation of affiliated region statistics, WM segmentation, tessellation and inflation of pial parcellated WM surfaces and cortical parcellation with calculation of cortical region

statistics. Four ROIs (amygdala, hippocampus, entorhinal cortex, precuneus), well known
to be affected early by AD pathology, were assessed<sup>45-47,17,48</sup>. Furthermore, anatomical
masks representing Braak stages were created following<sup>49</sup> and warped to MNI space.
Thus, the following cortical regions were included as aggregated volumes: stage I/II:
entorhinal cortex and hippocampus, stage III/IV: limbic, insular and temporal regions,
V/VI: remaining cortical regions including primary sensory/motor areas or precuneus.

268 In order to enable a reliable operationalization of the N category of ATN system we used the specifically developed hippocampal segmentation in Freesurfer that is based on a 269 high-resolution T2-weighted scan of the medial temporal lobe<sup>50</sup>. Note, that the obtained 270 271 hippocampal volumes were only used for the ATN classification of each participant, while all presented voxel-based and ROI volumes were based on conventional CAT and 272 Freesurfer segmentations (as dependent variable). A strong co-occurrence of AD and 273 white matter hyperintensities (WMH) as sign of vascular damage has been reported<sup>16,51-</sup> 274 <sup>54</sup>. To account for WMH during our analyses, the total lesion volume was extracted using 275 276 Lesion segmentation toolbox (v3.0.0, LPA and an 0.5 binary threshold, <sup>55,56</sup>).

#### 277 ATN classification and group comparison

Each participant was classified as normal (-) or abnormal (+) in the Amyloid (A) and Tau 278 (T) category depending on their biomarker levels of Aβ42over40 and phospho-Tau181 279 respectively. Cut-offs were estimated by a ROC analysis and Youden's index (A = 0.09, 280 T = 57 pg/ml; <sup>34</sup>). In this study we explored effects of two different choices for the 281 neurodegeneration (N) category. We focused on (1) adjusted hippocampal volume 282 (denoted as aHV; cut-off = 2821.1 µl) and (2) CSF Total Tau (cut-off = 470 pg/ml). aHV 283 was derived from the Freesurfer segmentation (see above) and corrected for age, sex, 284 education, total intracranial volume (TICV) and WMH using a linear regression model. 285

Dichotomization of participants' aHV into N- and N+ was performed using Gaussian mixture modelling similar to established cut-off estimation for CSF biomarkers used for the A and T category<sup>57</sup>.

289 To assess group differences in age and education, one-way ANOVAs with ATN status as between-subject variable were used. Group differences in cognition (MMSE and memory 290 performance) were tested in ANCOVAs with ATN status as between group variable and 291 age, sex and education as covariates. In all cases, post-hoc analysis was performed by 292 two sample t-tests using a Bonferroni correction to account for multiple comparisons. 293 Notably, analyses were restricted to the four groups of the ACH-based progression (1) A-294 295 T-N- (2) A+T-N- (3) A+T+N- (4) A+T+N+ since we focused on implications for common AD-related trajectories. The distribution of ATN status per clinical diagnosis was tested 296 by 2-sided Fisher's exact test for distribution differences between cognitively unimpaired 297 (NC, SCD) and cognitively impaired (MCI, DAT) subjects. Significance level is set to p < 298 .05 (\*) or p < .001 (\*\*) respectively. 299

# 300 Testing the evidence for a monotonic decrease of brain volume over ATN 301 progression groups

We aimed to test the evidence of local brain GM volume loss as a process of AD progression. As predicted by the ACH, the volume would decline over the following groups (1) A-T-N- (2) A+T-N- (3) A+T+N-; to (4) A+T+N+. Thus, we hypothesized later ATN stages to be associated with significantly reduced GM in AD-related areas. We estimated a voxel-wise general linear model describing the local GM volume *y* for the 4 given groups as

$$y = X\beta + \epsilon$$

with design matrix X, coefficients  $\beta$  and residuals  $\epsilon$ . The design matrix was chosen to define  $\beta_1$  as group mean of the first group, and for g=2,3,4 coefficient  $\beta_q$  as group difference of group g and g-1. The model was fitted under linear constraints that  $\beta_a \leq 0$ for q=2.3.4 and therefore implementing a monotonic decline of volume across groups 1 to 4 (using MATLAB R2019b's function for constrained optimization Isglin). For instance if a voxel has a true monotonic decline of volume y over groups 1,2,3,4 the model evidence is expected to be higher than for an alternative model with reversed group order e.g. 4,3,2,1. We further compared different hypothesized and alternative sequences of volume decline progressions using the Bayesian Information Criterion<sup>58</sup> (BIC) which compares the likelihood how well the data is described using a monotonic function while accounting for model complexity (Figure 1). 

#### 331 Figure 1: Monotonic and non-monotonic volume decline using ATN.



A: An illustration of monotonic GM volume decline as hypothesised when following the ACH hypothesis using ATN groups. B: A permutated order of the upper case that clearly not shows a monotonic volume decline. A temporarily volume increase causes large residuals that cannot be explained by a monotonic model. Therefore, the pathway in A would be preferred over B ('higher evidence for monotonic decline in A').

First, face validity of the ACH hypothesis was tested by comparing the evidence of the above ACH-based sequence  $(1) \rightarrow (2) \rightarrow (3) \rightarrow (4)$  against 23 (=4\*3\*2\*1-1) alternative monotonic progressions generated by permutation which are *a-priori* less plausible if ACH is true. Note that this analysis was restricted to 4 primarily AD-related of all 8 possible ATN classification groups, where it is assumed that Amyloid conversion happens before status conversion of Tau and Neurodegeneration. In a second analysis, the evidence of the ACH-related volume trajectory was compared against 5 biologically plausible alternative sequences including also ATN groups which are considered outside the ADcontinuum, in particular ANT (i.e. Amyloid-conversion first, N-conversion second, Tauconversion last; therefore 'ANT'), TAN, TNA, NAT, and NTA. These 6 sequences represent all conceivable possibilities to convert in three steps from A-T-N- (no pathology) to A+T+N+ (full pathology).

In this study, all tests were performed both on (A) whole brain voxel-based modulated GM volume images, and (B) a-priori hypothesized ROIs. Voxel-based tests were restricted to GM using an absolute threshold of .05. In addition, the percentage of voxels with the highest evidence for the ACH trajectory inside every ROI mask is provided.

All statistical analyses were performed in MATLAB. Voxel-wise test results are presented 354 as maps with the highest evidence for one particular model and log p maps for inference 355 on statistical parameters such as successive volume decline over groups (using FDR 356 correction for multiple comparisons, p<0.05). Finally, the percentage of GM voxels with 357 the highest evidence for a certain progression sequence is provided. All analyses were 358 accounting for covariates age, sex, education, TICV and WHM. All main results are 359 360 reported for N operationalized by aHV and selected results using CSF Total Tau can be found in the supplementary material. 361

- 362
- 363 Results

## 364 Sample demographics and ATN group comparisons

365 Key characteristics of the analysed sample are summarized in Table 1, selected 366 comparisons (Bonferroni) can be found in Figure 2. As expected we found that age

differed across ATN groups (F(7,429) = 6.65, p < .001). ATN groups showed also 367 368 differences in years of education (F(7,429) = 2.63, p < .05). With respect to cognition, we found a significant effect of ATN group (F(7,426) = 13.46, p < .001), age (F(1,426) = 369 14.78, p < .001) and education (F(1,426) = 19.58, p < .001) on MMSE scoring, but no 370 effect of sex (F(1,426) = 0.93, p = .33). Similar results were obtained for the memory 371 performance, where ATN status (F(7,426) = 28.10, p < .001), age (F(1,426) = 44.54, p < 372 .001), education (F(1,426) = 39.78, p < .001) and sex (F(1,426) = 3.87, p < .05) were 373 significant. 374

375 <u>Table 1: Sample and ATN group overview.</u>

	A-T-N-	A-T-N+	A-T+N-	A-T+N+	A+T-N-	A+T-N+	A+T+N-	A+T+N+
Group size	143	41	29	14	45	23	61	81
age (years)	69.64	68.10	70.20	70.86	69.97	70.91	73.20	73.46
mean (SD)	(5.50)	(5.85)	(4.56)	(5.90)	(5.12)	(7.10)	(5.30)	(5.84)
sex (% female)	48.25%	48.78%	72.41%	28.57%	42.22%	39.13%	47.54%	55.56%
education	14.65	14.71	13.79	16.57	14.07	14.43	13.67	13.75
years mean (SD)	(2.92)	(2.87)	(2.02)	(2.53)	(2.53)	(3.19)	(3.33)	(2.98)
MMSE	29.15	28.54	29.14	29.14	29.24	27.52	27.52	26.12
mean (SD)	(1.19)	(1.98)	(1.27)	(1.61)	(0.77)	(3.29)	(3.06)	(3.23)
Memory								
performanc	0.39	0.13	0.42	0.01	0.35	-0.52	-0.44	-1.18
е	(0.51)	(0.84)	(0.67)	(0.99)	(0.64)	(1.05)	(1.09)	(1.00)
mean (SD)								
CSF	0.110	0.108	0.112	0.118	0.074	0.064	0.053	0.050
Αβ42/40	(0.011)	(0.011)	(0.013)	(0.014)	(0.012)	(0.015)	(0.011)	(0.013)
mean (SD)	, ,	, ,	. ,	. ,	. ,	. ,	, ,	. ,
CSF	44.00	20.05	<b>CO 0</b> 2	74.00	44.00	44.40	02.26	
pnospno-	41.02	39.85	68.02	/4.68	41.88	44.49	93.26	95.06
mean (SD)	(8.81)	(11.84)	(10.88)	(19.41)	(9.99)	(9.40)	(50.38)	(31.09)
CSF Total	200.10	201.24	465.00	E 4 4 2 0	221 44	212.00	C77 44	770.42
Tau (pg/ml)	288.18	291.24	465.98	544.38	321.41	312.96	677.41	//8.43
mean (SD)	(89.16)	(131.09)	(115.59)	(167.71)	(104.50)	(94.48)	(335.83)	(287.03)
aHV (ml)	3.14	2.64	3.18	2.63	3.12	2.60	3.12	2.56
mean (SD)	(0.21)	(0.15)	(0.24)	(0.11)	(0.21)	(0.21)	(0.23)	(0.22)

WMH (ml)	3.29	3.27	1.42	2.09	3.19	4.66	6.99	6.34
mean (SD)	(5.31)	(6.07)	(1.70)	(2.83)	(3.61)	(6.05)	(11.61)	(7.96)

- Overview on test sample and ATN group statistics. aHV: adjusted hippocampal volume; WMH: white matter
   hyperintensities.
- As shown in Figure 2, the age increased while global cognition (MMSE) and memory performance decreased following a hypothesized disease progression using the ACH sequence (A-T-N-  $\rightarrow$  A+T-N-  $\rightarrow$  A+T+N-  $\rightarrow$  A+T+N+). No systematic pattern was found for years of education. These effects could be reproduced using CSF Total Tau for N (Supplemental File 1).

## 383 Figure 2: Comparison between selected ATN groups.



384

Boxplots of age, sex, cognition for selected ATN groups. \*: p < .05 after Bonferroni correction, \*\*: p < .001</li>
after Bonferroni correction.

## 387 Association of ATN status and clinical diagnosis

We observed an association of the ATN status and clinical diagnosis groups comparing cognitively unimpaired (NC, SCD) and cognitively impaired (MCI, DAT) participants for A-T-N- (p < .001), A-T+N- (p < .05), A+T-N- (p < .05), A+T+N- (p < .05) and A+T+N+ (p <

.001). No non-random association was found for A-T-N+ (p = .49), A-T+N+ (p = .40) and 391 A+T-N+ (p = .26). Compared to A-T-N-, the highest relative risk for DAT was found in 392 A+T+N+ (30.90 times higher) and A+T-N+ (15.54 times). The lowest risk for DAT relative 393 to A-T-N- was in A-T+N- (2.47 times higher), while no DAT cases were recorded in A-394 T+N+ or A+T-N-. Results suggested that more impaired clinical groups, especially DAT, 395 were found more often among the Alzheimer's continuum ATN groups (i.e. in A+), while 396 cognitively unimpaired status was rather associated to no brain pathology (i.e. A-T-N-). 397 For percentual distribution see Figure 3. A similar pattern was observed for N measured 398 by CSF Total Tau (Supplemental File 2). 399





401

402 Left: percentual distribution of selected ATN groups per clinical diagnosis; right: percentual distribution of 403 clinical diagnosis per ATN groups.

# 404 Assessing face validity of the ACH hypothesis using local brain volume

As a next goal, we identified brain regions where volume progression across ATN groups is compatible with the ACH hypothesis. More specifically, if the ACH is true it might be expected to observe a monotonic decline of volume over groups A-T-N-  $\rightarrow$  A+T-N-  $\rightarrow$ 

A+T+N-  $\rightarrow$  A+T+N+ in the hippocampal network<sup>25</sup>. The regions showing significant GM volume decline over this ACH sequence (of ATN biomarker conversions) are illustrated in Figure 4A (log p map, p < .05 FDR-corrected, N based on hippocampal volume, accounting for covariates age, sex, education, TICV and WMH). Strongest effects are found in the MTL region (peak: left post. hipp. x = -28, y = -22, z = -19, log p = 86.70). Further regions with significant GM volume loss following the ACH sequence are the orbital and basal forebrain, large parts of the temporal lobe, the insular cortex, the basal ganglia, the cingulate gyrus, the precuneus, (medial) premotor regions and the parietal and occipital lobes. When using CSF total Tau instead of hippocampal volume for operationalization of the 'N' category, we observed consistent but slightly less widespread shrinkage of local GM (peak: left ant. hipp. peak x = -26, y = -10, z = -17, log p = 21.41, Figure 4B). 

- A Neurodegeneration by a HV Neurodegeneration by a HV Neurodegeneration by CSF total Tau Neurodegeneration by
- 420 Figure 4: Volume decline following the ACH sequence.

Regions showing significant GM volume loss along the ACH sequence. Unmasked log p map with p < .05,</li>
FDR-corrected. A: Neurodegeneration (N) defined by aHV; B: Neurodegeneration (N) defined by CSF total

*Tau.* 

It is important to note that testing for 'any' local volume decline over groups that align with 425 the ACH-related progression might still reveal brain areas where alternative disease 426 progressions are even more likely. Therefore, in an explorative analysis we compared 427 voxel-wise evidence of the hypothesized ACH progression (or model) against 23 428 429 biologically less plausible (permuted) conversion sequences among the ATN classification groups associated with the AD continuum e.g. the above stated group 430 progression but in reversed order. First, we applied a voxel-based test of monotonic GM 431 volume decline using the Bayesian Information Criterion. Figure 5a illustrates the 432 resulting regions with highest evidence for three selected progressions. Since only one 433 434 sequence of diagnostic conversions can have the highest evidence in a given brain region 435 (when compared to other progressions), these maps revealed non-overlapping areas of the brain. For 8.99% of all explored GM brain regions, ACH was indeed found to be the 436 most evident progression sequence showing monotonic volume decline (Figure 5b). This 437 especially involved the anterior MTL, hippocampus, parahippocampal gyrus and fusiform 438 gyrus while the general pattern of regions most compatible with ACH is similar to the 439 above presented findings. 440

- 441
- 442
- 443
- 444
- 445
- 446

#### 448 Figure 5: Face validity of ACH using VBM.



449

450 Voxel-based evidence for monotonic volume decline over 24 sequences gained by permutation of the ACH 451 sequence (ACH, A-T-N- $\rightarrow$ A+T-N- $\rightarrow$ A+T+N+); AP 1: A+T-N- $\rightarrow$ A+T+N- $\rightarrow$ A-T-N- $\rightarrow$ A+T+N+; AP 2: 452 A+T-N- $\rightarrow$ A-T-N- $\rightarrow$ A+T+N- $\rightarrow$ A+T+N+; A: voxels where sequence shows highest evidence; B: percentage 453 of gray matter voxels where sequence has highest evidence.

However, this analysis also suggested that the ACH sequence was not the most evident 454 progression (among 24 tested) in frontal lobe, insular cortex, precentral and postcentral 455 gyri or the cerebellum. Our analysis revealed several brain regions in which alternative 456 sequences over ATN groups were better reflective of monotonic volumetric decline. More 457 specifically, alternative progressions AP 1 (A+T-N- $\rightarrow$ A+T+N- $\rightarrow$ A-T-N- $\rightarrow$ A+T+N+) and AP 458 2 (A+T-N- $\rightarrow$ A-T-N- $\rightarrow$ A+T+N- $\rightarrow$ A+T+N+) showed highest evidence in 16.28% and 459 14.05% of the GM respectively (Figure 5). Interestingly, both assume a transient volume 460 increase when transitioning to Amyloid-positivity (i.e. GM volume of A+T-N- > A-T-N-) 461 followed by the lowest GM volume in A+T+N+. AP 1 was the conversion sequence having 462 highest evidence in cortical regions (especially frontal lobe, orbital frontal, premotor 463

regions, insular cortex). AP 2 showed highest evidence in parts of the posterior MTL, the
 middle and posterior cingulate gyrus, and cortical clusters (the precuneus, temporal,
 parietooccipital lobe).

467 Table 2 shows the results for a similar but complementary ROI-level analysis of monotonic GM decline in amygdala, hippocampus, entorhinal cortex and precuneus 468 defined using an MRI atlas. The ACH-based progression was found to be the best fitting 469 sequence to describe monotonic GM volume loss in amygdala and entorhinal cortex. For 470 all ROIs, the ACH progression was found to be among top 5 most likely sequences (out 471 of 24). Surprisingly, AP 1 showed highest evidence for hippocampal ROI volume loss, 472 while the precuneus volume was best described by AP 2. One potential disadvantage of 473 the definition of the 'N' category is the dependence on atlas-based ROIs, e.g. for the 474 hippocampus. When using CSF Total Tau for definition of the 'N' category, the ACH 475 sequence was also found to optimally describe monotonic GM loss especially in the MTL. 476 On ROI level the ACH sequence was always the most or second most evident pathway 477 478 (out of 24; Supplemental File 3&4).

479	Table 2: Face validity	v of ACH in selected ROIs.
		,

Region	Sequence with	т	Р	ACH on rank	ACH	
0	highest evidence			nr. (of 24)	VX%	
AMG	ACH	-13.69	2.53e-34	1	80.99	
Hippocampus	AP 1	-14.88	6.76e-39	5	26.27	
Entorhinal	АСН	-7 30	1 130-12	1	48 46	
Cortex	AON	-7.50	1.106-12	I	-00	
Precuneus	AP 2	-3.90	5.76e-05	4	13.78	
Braak I/II	ACH	-16.11	1.15e-43	1	25.13	
Braak III/IV	Other1	-6.97	8.59e-12	5	17.97	
Braak V/VI	Other1	5.06	3.54e-07	5	7.31	

480 ROI based testing for monotonic volume decline over 24 sequences gained by permutation of the ACH 481 sequence. Braak stage volumes are aggregated Freesurfer ROI volumes. ACH: A-T-N- $\rightarrow$ A+T-N- $\rightarrow$ A+T+N-

482  $\rightarrow A+T+N+; AP 1: A+T-N-\rightarrow A+T+N-\rightarrow A-T-N-\rightarrow A+T+N+; AP 2: A+T-N-\rightarrow A-T-N-\rightarrow A+T+N+;$ 

483 Other1:  $A+T+N- \rightarrow A+T-N- \rightarrow A-T-N- \rightarrow A+T+N+$ . ACH VX%: Percentage of voxels with highest evidence 484 for ACH sequence inside the ROI mask.

#### 485 **Comparing progression sequences towards AD pathology including non-AD**

#### 486 continuum groups

487 All above comparisons were focused on only four ATN groups from the AD continuum (A-T-N-, A+T-N-, A+T+N-, A+T+N+). However, these AD continuum-related groups do not 488 enable direct comparisons of ACH-implied conversion sequences against an alternative 489 timing of events such as Tau positivity preceding Amyloid positivity (e.g. A-T+N+ 490 converting to A+T+N+). We therefore compared the ACH-based sequence to five other 491 biologically possible conversion schemes from A-T-N- towards A+T+N+ (denoted as 492 ANT, TAN, TNA, NAT, NTA). For this comparison the conversion sequences are denoted 493 in the order of each biomarker becoming positive, e.g., TAN stands for: Tau category 494 becomes positive first, Amyloid second, Neurodegeneration last (A-T-N-  $\rightarrow$  A-T+N-  $\rightarrow$ 495  $A+T+N- \rightarrow A+T+N+$ ). Again, Bayesian Information Criterion (BIC) was used to identify 496 conversion sequences with highest evidence for monotonic volume decline both on a 497 voxel as well as ROI-level. 498

Brain regions with highest evidence for above progressions are characterized in Figure 499 500 6. According to our analysis A-first sequences (ACH/ATN, ANT), T-first sequences (TAN, TNA) and N-first sequences (NAT, NTA) showed the highest evidence for monotonic 501 volume decline in 64%, 35% and 0.01% of GM respectively. Local GM regions with 502 highest likelihood for ACH were especially found in the MTL (with an exception of the right 503 anterior hippocampus and parahippocampal gyrus), but also in the basal ganglia (caudate 504 ncl., putamen, thalamus) and precuneus. More supporting clusters for ACH/ATN were 505 observed in all cortical lobes making it clearly the most likely sequence in large parts of 506 GM in this comparison. The ANT progression showed highest evidence in complementary 507

regions of the MTL not covered by ACH/ATN (see above) with additional regions in the basal ganglia (ncl. accumbens), medial frontal lobe, the insular cortex and premotor regions. T-first sequences were most likely only in the cerebellum and some cortical regions including the medial occipital lobe. All of these four sequences showed evidence for different parts of the cingulate gyrus. N-first sequences were only seen in very minor portions of the GM.

514 Figure 6: Comparing progression sequences towards AD pathology using VBM.



515

Regions with highest evidence for monotonic volume decline assuming 6 potential disease progressions from A-T-N- towards A+T+N+ (ACH, ANT, TAN, TNA, NAT, NTA). Sequences are denoted in the order of biomarker positivity along the pathway (e.g. ANT = Amyloid-positivity first, Neurodegeneration second, Tau last). A: voxels where sequence shows highest evidence; Notably, regions of highest evidence for each progression are disjunct. B: percentage of gray matter voxels where sequence has highest evidence. Nfirst sequences (NAT, NTA) are not shown as only few voxels are supported.

In the complementary ROI analysis, conversion sequences with monotonic volume decline were compared for same ROIs as above. The most evident sequences for volume

loss per ROI and matching effect size are presented in Table 3. Interestingly, ACH/ATN 524 was the most evident progression for amygdala, entorhinal cortex and precuneus. In 525 hippocampus however, the ANT progression was found to show the highest evidence for 526 the data. Our analysis revealed no indications for the superiority of T-first or N-first over 527 A-first sequences in these ROIs. Notably, above findings were mainly reproduced using 528 CSF Total Tau as neurodegeneration marker. Here, ACH was also the most prominent 529 sequence: On voxel-level, more than 41% of GM showed highest evidence for the ACH 530 sequence (Supplemental File 5). On ROI-level, ACH was the most evident sequence with 531 exception of amygdala and entorhinal cortex, where TAN was more likely which is in 532 contrast to the results of aHV-based Neurodegeneration (Supplemental File 6). 533

## 534 Table 3: Comparing progression sequences towards AD pathology including non-AD

535	continuum	aroups	in	selected	ROIs.
555	oontiniaann	groupo		00100100	110101

Pagion	Rost coquence	т	D	ACH on rank	ACH	
Region	Dest sequence	I	F	nr. (of 6)	VX%	
AMG	ACH	-12.93	8.22e-33	1	89.62	
Hippocampus	ANT	-18.07	5.74e-55	2	58.18	
Entorhinal	АСН	-7.25	0 780-13	1	80.05	
Cortex	ACIT	-1.25	9.700-13	I	03.00	
Precuneus	ACH	-3.93	4.86e-05	1	30.92	
Braak I/II	ACH	-16.20	1.07e-46	1	57.95	
Braak III/IV	ANT	-7.67	5.64e-14	2	46.02	
Braak V/VI	ANT	-4.21	1.53e-05	2	28.60	

ROI based testing for monotonic volume decline over 6 possible sequences from A-T-N- towards A+T+N+
(ACH, ANT, TAN, TNA, NAT, NTA). Braak stage volumes are aggregated Freesurfer volumes of regions
that mirror Braak stages. ACH VX%: Percentage of voxels with highest evidence for ACH sequence inside
the ROI mask.

# 540 Concordance of Braak stage trajectory and the ACH trajectory

541 In addition to above reported ROIs, the two voxel-based analyses of compatibility of the

542 ACH sequence with monotonic GM volume decline were aggregated for larger Braak

stage composite regions (Table 2 & 3). Here, stage I/II encompasses the hippocampus 543 and entorhinal cortex, stage III/IV the limbic regions and stage V/VI the remaining cortical 544 regions like precuneus or primary sensory/motor regions. We asked, how much of GM at 545 some stage showed highest evidence for ACH. On voxel-level, the percentage of voxels 546 with highest evidence for the ACH sequence decreased from 25.1% in stage I/II to 7.3% 547 in stage V/VI for the first comparison (face validity of ACH). For the second comparison 548 (including non-AD continuum groups) there was also a noticeable decrease of ACH 549 compatible GM voxels from 58.0% in stage I/II to 28.6% in stage V/VI (see Table 2 & 3). 550

Thus, on ROI-level, ACH-related ATN sequence across groups was the most evident 551 552 conversion sequence which is compatible with a monotonic volume decline in Braak stage I/II. For ROIs reflecting stages III/IV and V/VI, ACH was under the most evident 5 (of 24) 553 respectively 2 (of 6) sequences and thus not the most likely explanation for decline 554 anymore. Test statistics and p-values were decreasing with higher Braak stages (stage 555 I/II & III/IV: p < .001; V/VI: p < .05) which supports that ACH compatibility reduces with 556 557 Braak stage. Using CSF Total Tau instead of hippocampal volume, a similar trend was observed while more voxels supported ACH in stage I/II (stage I/II & III/IV: p < .001; V/VI: 558 p > .05), Supplemental File 3&6). 559

560

# 561 **Discussion**

562 Since the ATN classification was postulated in 2016<sup>24</sup>, several studies compared ATN 563 groups to a traditional clinical dementia classification<sup>26,27,59,30,29,60,61</sup>. However, a 564 discussion of ATN in context of biological or structural brain changes during AD including 565 local (e.g. voxel-based) brain morphology and the Amyloid Cascade Hypothesis (ACH)

can be found to a much lesser extent in previous research<sup>31-33</sup>. This study aimed to focus
on these neglected aspects of interest.

568 Our comparison between ATN status and clinical diagnosis suggested advanced clinical 569 diagnostic status with increasing pathology levels following the ACH group conversion 570 sequence. This is consistent with earlier work<sup>27,59,30</sup> where a similar pattern has been 571 observed. The A+T+N+ group has previously been reported to show the highest 572 conversion rate to DAT and an increased risk for cognitive decline<sup>26,27,29,60,30,61</sup>. In line 573 with these findings our results suggested substantial memory performance reductions in 574 later ATN stages.

Using MRI and voxel-based morphometry (VBM) we first tested the face validity of a 575 monotonic GM volume decline over the 4 ATN stages (1) A-T-N- (2) A+T-N- (3) A+T+N-576 (4) A+T+N+ as implied by the ACH and previous work suggesting GM volume loss during 577 ACH progression in clinical DAT. In contrast to previous with strong prior assumptions 578 579 about ROIs, our emphasize here was on reporting also complementary voxel-based results. More specifically, in line with previous findings brain regions following monotonic 580 volume decline over ATN stages (1)-(4) involved the hippocampus<sup>62,17,46,45,63-68</sup>, 581 amygdala<sup>62,17,46,45,65,67,68</sup>, temporal gyri<sup>17,46,64,66,67</sup>, thalamus<sup>62,17,65,63</sup>, precuneus<sup>62,17,64,66</sup> 582 and cingulate gyrus<sup>62,17,63,64,66,69</sup>. Consistent with some previous work<sup>69,63,66</sup> a decline in 583 parts of the cingulate gyrus and insula were observed in our study. Regions that are 584 expected to be affected in very late AD such as frontal<sup>17,66</sup> and occipital<sup>64,45,63,66</sup> lobes or 585 less affected such as those around central sulcus<sup>46,64,66</sup> showed only minor effects in 586 terms of a monotonic decline over ATN stages (1)-(4). 587

588 Notably the ACH is still part of an ongoing discussion as anti-amyloid treatments showed 589 only limited success<sup>70,71</sup>. Furthermore, the causal link between Amyloid, Tau and resulting

neurodegeneration and dementia is a challenging research topic<sup>19,20</sup> which might be 590 mediated by alterations in neuropil<sup>71</sup>, synapses<sup>72</sup> or functional connectivity<sup>73</sup>. Our study 591 revealed strong evidence for an ACH-related monotonic atrophy pattern both on voxel-592 level but also on ROI-level especially focussed on typical AD-related regions such as the 593 MTL. However, we also observed many gray matter areas where a monotonic volume 594 trajectory along the ACH-implied group progression sequence did show the highest 595 evidence. We identified alternative progressions (denoted AP 1 and AP 2) indicating that 596 there are several cortical regions where the GM volume was found to be higher in the 597 A+T-N- group than in A-T-N-. These were mainly found in cortical regions which are often 598 599 less strongly affected by AD<sup>66,17</sup>. One might speculate that either Amyloid deposition related tissue expansion<sup>74,75</sup> and/or sampling effects due to individual differences of brain 600 reserve<sup>76</sup> might alter brain volume patterns across ATN groups and the progression along 601 602 the ACH trajectory. A biphasic model of neurodegeneration has been previously suggested by Fortea et al.<sup>74</sup> hypothesizing that cortical thickening might occur when Aß 603 becomes abnormal, which presumably reflects inflammation-related swelling, followed by 604 thinning once tau pathology emerges. The authors found Amyloid-related thickness 605 increases in middle temporal, inferior and superior parietal, occipital regions and 606 607 precuneus which is similar to our findings. Another recent publication also observed Amyloid-related regional volume increase in A+T-N- for the basal forebrain, postcentral 608 gyrus, middle occipital gyrus, and putamen when comparing to A-T-N-77. As described 609 610 above, large parts of the cingulate gyrus did suggest a monotonic volume decline along ACH group progression. However, ACH did not necessarily reveal the highest evidence 611 in the entire cingulate as there were also portions with highest evidence for non-612 monotonic volume decline (subcallosal to middle cingulate in AP1 & middle to posterior 613

cingulate in AP2). This renders the cingulate a potential candidate region for brain reserveor biphasic model that requires further research.

Under the assumption that patients will convert from negative to positive ATN biomarkers, 616 617 six patterns of conversions are possible when non-AD pathology ATN groups are additionally included. When testing for monotonic volume decline across these patterns, 618 the highest evidence was found for sequences where Amyloid converts before either Tau 619 or Neurodegeneration (e.g. ATN, ANT), and this was observed in 65% of all gray matter 620 brain areas, especially in AD-related regions. We were able to replicate our finding using 621 ROI-based analyses. In contrast, conversion patterns where Tau converted before 622 Amyloid (TAN, TNA) showed highest evidence for a monotonic volume decline in cortical 623 regions that are atypical for AD pathology. Support for our findings comes from a 624 longitudinal study of 262 non-demented elderly to monitor ATN biomarker progress<sup>32</sup>. It 625 was found that ACH was the most common path of biomarker conversion, but also ANT, 626 TAN and NAT occurred. In contrast, we observed no evidence for NAT in terms of GM 627 volume decreases. It is worth mentioning that per definition, A-T+ or A-N+ groups are not 628 part of the AD-continuum, these groups might initially point to other diseases like primary 629 tauopathies, hippocampal sclerosis/TDP-43 or ischaemic diseases<sup>24</sup>. As remarked by <sup>1</sup> 630 and <sup>32</sup>, the occurrence of conversion sequences other than ACH in real world data might 631 be explained (a) by coincidence of AD- and non-AD pathologic changes (e.g. in A+T-N+) 632 or (b) long-time subthreshold biomarker trends matching the ACH that are not recognized 633 due to a binary classification with disadvantageous thresholds<sup>1,32</sup>. Another study provides 634 more support for our hypothesis of an ACH-related temporal order of biomarker progress 635 636 by monitoring between-group biomarker changes in an longitudinal approach using the ATN classification<sup>31</sup>. 637

Furthermore, our morphometric study revealed evidence to support the consistency 638 between the ACH and Braak staging. Brain regions that are expected to be earlier 639 affected by AD-pathology-linked tau deposition (stage I-IV, MTL, limbic system) showed 640 stronger evidence for monotonic GM volume decline over a sequence of conversions than 641 642 later stages (stage V/VI, cortical regions). As it is already known that brain atrophy often follows Tau and NFT aggregation<sup>65</sup>, both hypotheses were not mutually exclusive. In our 643 analysis, the stronger evidence for volume decline in the amygdala was surprising when 644 comparing to the hippocampus. As <sup>78</sup> remarked, Tau pathology in the amygdala is already 645 beginning with Braak stage I/II. However, this effect was not reproducible with 646 647 Neurodegeneration by CSF Total Tau.

It is known that alternative choices of markers for the N category may have a strong 648 impact on ATN status assignment and longitudinal prediction of cognition<sup>79,80</sup>. The large 649 pool of possible classification methods limits intercomparability between ATN studies 650 dramatically. In our large study, both variants of ATN classification approaches showed 651 652 converging evidence for the ACH hypothesis. We were not able to determine a superior combination, as both tested N markers have advantages and caveats. The usage of aHV 653 leads to overall stronger effect sizes but one might argue that there is a circularity in 654 defining ATN groups using volumetry and analyzing ATN-related local brain 655 morphometry. Neurodegeneration defined by aHV is a discrete marker of general 656 neuronal loss and the group assignment was carried out using a ROI-rather than voxel-657 based approach. GM volume (as analyzed by VBM) on the other hand allows a 658 continuous whole brain local analysis on voxel-level and does not align with N for most 659 660 brain regions.

661 Although VBM revealed the highest evidence for ACH-related monotonic volume decline 662 in the hippocampus, regions in cortical areas showed compatible monotonic

progressions. Taking advantage of the voxel-based approach, differences between 663 sequences could be identified even inside the hippocampus (ACH supports anterior 664 Hippocampus, AP2 posterior hippocampus). It is worth mentioning that the approach is 665 not limited to VBM measurements, in contrast to developmental and plasticity studies 666 stronger expectations for monotonic trajectories do exist for brain volumes in aging and 667 AD. Alternative N categories (such as CSF Total Tau) might also have limitations. The 668 combination of CSF phospho-Tau (T category) and CSF Total Tau (N category) is used 669 in some studies<sup>26,60,61</sup>, while a strong correlation between both markers strongly 670 underrepresents some ATN groups (A?T+N-, A?T-N+). In a recent publication<sup>28</sup> it was 671 672 possible to replace CSF Total Tau by CSF phospho-Tau without significant impact on the model. Although there is only a weak correlation between aHV and CSF Total Tau as N 673 markers in our study, a similar pattern of local GM volume decline was revealed. This 674 further suggests that a morphometrical analysis with aHV is applicable. 675

# 676 Limitations

This study has several methodological limitations. The first challenge was the 677 hippocampal cut-off estimation: The large sample size does not allow to perform atrophy 678 679 reference methods like autopsy or visual rating of FDG-PET or MRI. Thus, no estimation of sensitivity or specificity was possible, which prohibits a ROC analysis and Youden's 680 index. Although aHV has a clear unimodal gaussian distribution, it is possible to perform 681 a Gaussian mixture modelling to separate between normal and decreased volumes. A 682 similar approach was performed by<sup>77</sup>. As our data is cross-sectional, no real progression 683 over disease progression and conversions can be modelled and tested. We compensated 684 potential influences of covariates by correcting for demographic marker such as age, sex 685 and education, vascular damage and intracranial volume. This improves comparability 686 687 (matching) across different ATN groups and increases validity of the underlying cross-

sectional progression. Once available, longitudinal DELCODE follow-up data will be usedfor further validation.

# 691 Conclusion

Early Amyloid status conversion (before Tau and Neurodegeneration) aligns with pattern of brain volume loss observed during AD progression. The ATN classification and the Amyloid cascade hypothesis are compatible with a monotonic progression of MTL atrophy but using the ATN classification system for staging our study revealed indications for non-monotonic progressions in other areas such as several cortical fields. 

# 709 Glossary

ACH	Amyloid Cascade Hypothesis
AD	Alzheimer's disease
DAT	Dementia of Alzheimer's type
aHV	Adjusted hippocampal volume
AN(C)OVA	Analysis of (co-) variance
ATN	Classification based on Amyloid / Tau / Neurodegeneration pathology
BIC	Bayesian Information Criterion
CAT	Computational Anatomy Toolbox
CDR	Clinical Dementia Rating
CERAD	Consortium to establish a registry for Alzheimer's disease
NC	Non-complaining healthy control
CSF	Cerebrospinal fluid
FDR	False Discovery Rate
FLAIR	Fluid attenuated inversion recovery
GM	Gray matter
MCI	Mild Cognitive Impairment
MMSE	Mini-mental state examination
MPRAGE	Magnetization prepared rapid gradient echo

- MRI Magnetic resonance imaging
- MTL Medial temporal lobe
- NFT Neurofibrillary tangles
- ROI Region of interest
- SCD Subjective Cognitive Decline
- SPM Statistical Parametric Mapping
- TICV Total intracranial volume
- VBM Voxel-based Morphometry
- WM White matter
- WMH White matter hyperintensities

- 711
- 712
- 713
- 714
- 715
- 716
- 717
- 718
- 719

# 720 **Declarations**

#### 721 Ethics approval and consent to participate

DELCODE is retrospectively registered at the German Clinical Trials Register (DRKS00007966), (04/05/2015) and was approved by ethical committees and local

review boards. All participants gave written informed consent to participate.

#### 725 **Consent for publication**

726 Not applicable

#### 727 Availability of Data and Materials

The code used during the current study are available from the corresponding author on reasonable request. Data, study protocol and biomaterials can be shared with partners based on individual data- and biomaterial transfer agreements. Requests can be addressed to the DELCODE steering committee.

#### 732 Competing Interests

The authors declare that they have no competing interests.

## 734 **Funding**

The study was funded by the German Center for Neurodegenerative Diseases
(Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE)), reference number
BN012.

#### 738 Author's contributions

- The study was designed by E.D., M.W., A.S. and F.J. Data analysis was performed by
- N.H. N.H., G.Z., and E.D. wrote the manuscript. All authors reviewed the paper.

# 741 Acknowledgements

- 742 Not applicable

- / 50

# 761 Supplement

# 762 Supplemental File 1: Comparison between selected ATN groups using CSF-total-Tau.



Boxplots of age, sex, cognition for selected ATN groups. \*: p < .05 after Bonferroni correction, \*\*: p < .001after Bonferroni correction. Neurodegeneration (N) by CSF Total Tau.

- ,,,

# 776 Supplemental File 2: Distribution of ATN status and clinical diagnosis using CSF-total-

## 777 <u>Tau.</u>



779 Left: percentual distribution of selected ATN groups per clinical diagnosis; right: percentual distribution of

780 clinical diagnosis per ATN groups. Neurodegeneration (N) by CSF Total Tau.

## 790 Supplemental File 3: Face validity of ACH using selected ROIs and CSF-total-Tau.

Region	Best sequence	Т	Р	ACH on rank nr. (of 24)	ACH VX%
AMG	Other2	-7.10	3.17e-12	2	14.42
Hippocampus	ACH	-6.20	7.34e-10	1	47.86
Entorhinal	Other?	-1 71	1 730-06	2	13 01
Cortex	Otherz	-4.71	1.736-00	2	43.34
Precuneus	Other3	-2.35	.0095	2	18.00
Braak I/II	ACH	-6.65	5.10e-11	1	50.38
Braak III/IV	Other2	-4.52	4.16e-06	2	16.58
Braak V/VI	Other2	-1.64	.0513	2	5.52

791 ROI based testing for monotonic volume decline over 24 sequences gained by permutation of the ACH

792 sequence. Braak stage volumes are aggregated Freesurfer ROI volumes. Other2: A-T-N- → A+T+N- →

 $A+T-N- \rightarrow A+T+N+$ ; Other3:  $A+T-N- \rightarrow A-T-N- \rightarrow A+T+N- \rightarrow A+T+N+$ . ACH VX%: Percentage of voxels

with highest evidence for ACH sequence inside the ROI mask. Neurodegeneration (N) by CSF Total Tau.

## 806 Supplemental File 4: Face validity of ACH using VBM and CSF-total-Tau.



Voxel-based evidence for monotonic volume decline over 24 sequences gained by permutation of the ACH sequence (ACH, A-T-N- $\rightarrow$ A+T-N- $\rightarrow$ A+T+N+); AP 1: A+T-N- $\rightarrow$ A+T+N- $\rightarrow$ A-T-N- $\rightarrow$ A+T+N+; AP 2: A+T-N- $\rightarrow$ A-T-N- $\rightarrow$ A+T+N- $\rightarrow$ A+T+N+; A: voxels where sequence shows highest evidence; B: percentage of gray matter voxels where sequence has highest evidence. Neurodegeneration (N) by CSF Total Tau.

#### 821 Supplemental File 5: Comparing progression sequences towards AD pathology using

#### 822 VBM and CSF-total-Tau.



823

Voxel-based evidence for monotonic volume decline over 6 possible sequences from A-T-N- towards A+T+N+ (ACH, ANT, TAN, TNA, NAT, NTA). Sequences are denoted in the order of biomarker positivity along the pathway (e.g. ANT = Amyloid-positivity first, Neurodegeneration second, Tau last). A: voxels where sequence shows highest evidence; B: percentage of gray matter voxels where sequence has highest evidence. N-first sequences (NAT, NTA) are not shown as only few voxels are supported. Neurodegeneration (N) by CSF Total Tau.

830

831

- 832
- 833

#### 835 <u>Supplemental File 6: Comparing progression sequences towards AD pathology using</u>

#### 836 selected ROIs and CSF-total-Tau.

Pagion	Rost coguonco	т	D	ACH on rank	ACH	
Region	Dest sequence	I	F	nr. (of 6)	VX%	
AMG	TAN	-6.83	1.48e-11	5	49.06	
Hippocampus	ACH	-6.13	9.81e-10	1	75.41	
Entorhinal	ΤΔΝ	-1 67	2,060-06	2	72 55	
Cortex		-4.07	2.008-00	2	12.00	
Precuneus	ACH	-2.85	.0023	1	54.50	
Braak I/II	ACH	-6.53	9.41e-11	1	76.52	
Braak III/IV	ACH	-4.34	8.72e-06	1	50.96	
Braak V/VI	ACH	-1.60	.0557	1	39.84	

837 ROI based testing for monotonic volume decline over 6 possible sequences from A-T-N- towards A+T+N+

838 (ACH, ANT, TAN, TNA, NAT, NTA) including also non-AD continuum groups. Braak stage volumes are

839 aggregated Freesurfer ROI volumes. ACH VX%: Percentage of voxels with highest evidence for ACH

840 sequence inside the ROI mask. Neurodegeneration (N) by CSF Total Tau.

- 841
- 842
- 843
- 844
- 845
- 846
- 847
- ·
- 848
- 849
- 850
- 851
- 852

# 853 **References**

- Jack CR, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease:
   an updated hypothetical model of dynamic biomarkers. *The Lancet Neurology*. 2013;12(2):207-216.
   doi:10.1016/S1474-4422(12)70291-0
- Villemagne VL, Burnham S, Bourgeat P, et al. Amyloid β deposition, neurodegeneration, and
   cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. *The Lancet Neurology*.
   2013;12(4):357-367. doi:10.1016/S1474-4422(13)70044-9
- Dean DC, Jerskey BA, Chen K, et al. Brain differences in infants at differential genetic risk for late onset Alzheimer disease: a cross-sectional imaging study. *JAMA Neurol*. 2014;71(1):11-22.
   doi:10.1001/jamaneurol.2013.4544
- 4. Thal DR, Capetillo-Zarate E, Del Tredici K, Braak H. The development of amyloid beta protein
  deposits in the aged brain. *Sci Aging Knowledge Environ*. 2006;2006(6):re1.
  doi:10.1126/sageke.2006.6.re1
- 866 5. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. *Acta Neuropathol*.
  867 1991;82(4):239-259. doi:10.1007/bf00308809
- Banelidze S, Zetterberg H, Mattsson N, et al. CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic
   markers of Alzheimer disease. *Ann Clin Transl Neurol*. 2016;3(3):154-165. doi:10.1002/acn3.274
- 870 7. Ritchie C, Smailagic N, Noel-Storr AH, Ukoumunne O, Ladds EC, Martin S. CSF tau and the CSF
  871 tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people
  872 with mild cognitive impairment (MCI). *Cochrane Database Syst Rev.* 2017;3:CD010803.
  873 doi:10.1002/14651858.CD010803.pub2
- 874 8. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. *The Lancet Neurology*.
   875 2003;2(10):605-613. doi:10.1016/s1474-4422(03)00530-1
- Hampel H, Bürger K, Teipel SJ, Bokde ALW, Zetterberg H, Blennow K. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. *Alzheimers Dement*. 2008;4(1):38-48. doi:10.1016/j.jalz.2007.08.006
- 10. Nathan PJ, Lim YY, Abbott R, et al. Association between CSF biomarkers, hippocampal volume and
  cognitive function in patients with amnestic mild cognitive impairment (MCI). *Neurobiol Aging*.
  2017;53:1-10. doi:10.1016/j.neurobiolaging.2017.01.013
- 882 11. Selkoe DJ. The molecular pathology of Alzheimer's disease. *Neuron*. 1991;6(4):487-498.
   883 doi:10.1016/0896-6273(91)90052-2
- 12. Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. *Science*.
  1992;256(5054):184-185. doi:10.1126/science.1566067
- Reitz C. Alzheimer's disease and the amyloid cascade hypothesis: a critical review. *Int J Alzheimers Dis*. 2012;2012:369808. doi:10.1155/2012/369808
- 14. Hou Y, Dan X, Babbar M, et al. Ageing as a risk factor for neurodegenerative disease. *Nat Rev Neurol*.
  2019;15(10):565-581. doi:10.1038/s41582-019-0244-7
- 15. Yamazaki Y, Zhao N, Caulfield TR, Liu C-C, Bu G. Apolipoprotein E and Alzheimer disease:
  pathobiology and targeting strategies. *Nat Rev Neurol*. 2019;15(9):501-518. doi:10.1038/s41582019-0228-7
- Prins ND, Scheltens P. White matter hyperintensities, cognitive impairment and dementia: an
  update. *Nat Rev Neurol*. 2015;11(3):157-165. doi:10.1038/nrneurol.2015.10
- Yang J, Pan P, Song W, et al. Voxelwise meta-analysis of gray matter anomalies in Alzheimer's
   disease and mild cognitive impairment using anatomic likelihood estimation. *J Neurol Sci.*
- 897 2012;316(1-2):21-29. doi:10.1016/j.jns.2012.02.010

- 18. Matsuda H. Voxel-based Morphometry of Brain MRI in Normal Aging and Alzheimer's Disease. Aging
   and Disease. 2013;4(1):29-37. Accessed December 2, 2020.
- 900 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3570139/
- 901 19. A. Armstrong R. A critical analysis of the 'amyloid cascade hypothesis'. *fn*. 2014;3:211-225.
  902 doi:10.5114/fn.2014.45562
- 903 20. Busche MA, Hyman BT. Synergy between amyloid-β and tau in Alzheimer's disease. *Nat Neurosci*.
   904 2020;23(10):1183-1193. doi:10.1038/s41593-020-0687-6
- 21. Schöll M, Lockhart SN, Schonhaut DR, et al. PET Imaging of Tau Deposition in the Aging Human Brain.
   *Neuron*. 2016;89(5):971-982. doi:10.1016/j.neuron.2016.01.028
- 22. Maass A, Landau S, Baker SL, et al. Comparison of multiple tau-PET measures as biomarkers in aging
  and Alzheimer's disease. *Neuroimage*. 2017;157:448-463. doi:10.1016/j.neuroimage.2017.05.058
- 23. Matsuda H. MRI morphometry in Alzheimer's disease. *Ageing Res Rev.* 2016;30:17-24.
  doi:10.1016/j.arr.2016.01.003
- 24. Jack CR, Bennett DA, Blennow K, et al. A/T/N: An unbiased descriptive classification scheme for
   Alzheimer disease biomarkers. *Neurology*. 2016;87(5):539-547.
- 913 doi:10.1212/WNL.00000000002923
- 914 25. Jack CR, Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological definition of
  915 Alzheimer's disease. *Alzheimers Dement*. 2018;14(4):535-562. doi:10.1016/j.jalz.2018.02.018
- 26. Soldan A, Pettigrew C, Fagan AM, et al. ATN profiles among cognitively normal individuals and
  longitudinal cognitive outcomes. *Neurology*. 2019;92(14):e1567-e1579.
  doi:10.1212/WNL.00000000007248
- 27. Altomare D, Wilde A de, Ossenkoppele R, et al. Applying the ATN scheme in a memory clinic
  population: The ABIDE project. *Neurology*. 2019;93(17):e1635-e1646.
  doi:10.1212/WNL.00000000008361
- 922 28. van Maurik IS, Vos SJ, Bos I, et al. Biomarker-based prognosis for people with mild cognitive
  923 impairment (ABIDE): a modelling study. *The Lancet Neurology*. 2019;18(11):1034-1044.
  924 doi:10.1016/S1474-4422(19)30283-2
- 29. Jack CR, Wiste HJ, Therneau TM, et al. Associations of Amyloid, Tau, and Neurodegeneration
  Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia. *JAMA*.
  2019;321(23):2316-2325. doi:10.1001/jama.2019.7437
- 30. Yu J-T, Li J-Q, Suckling J, et al. Frequency and longitudinal clinical outcomes of Alzheimer's AT(N)
  biomarker profiles: A longitudinal study. *Alzheimers Dement*. 2019;15(9):1208-1217.
  doi:10.1016/j.jalz.2019.05.006
- 931 31. Guo T, Korman D, Baker SL, Landau SM, Jagust WJ. Longitudinal Cognitive and Biomarker
   932 Measurements Support a Unidirectional Pathway in Alzheimer's Disease Pathophysiology. *Biol* 933 *Psychiatry*. 2020. doi:10.1016/j.biopsych.2020.06.029
- 32. Tan M-S, Ji X, Li J-Q, et al. Longitudinal trajectories of Alzheimer's ATN biomarkers in elderly persons
  without dementia. *Alzheimers Res Ther*. 2020;12(1):55. doi:10.1186/s13195-020-00621-6
- 33. Ekman U, Ferreira D, Westman E. The A/T/N biomarker scheme and patterns of brain atrophy
  assessed in mild cognitive impairment. *Sci Rep.* 2018;8(1):8431. doi:10.1038/s41598-018-26151-8
- 34. Jessen F, Spottke A, Boecker H, et al. Design and first baseline data of the DZNE multicenter
  observational study on predementia Alzheimer's disease (DELCODE). *Alzheimers Res Ther*.
  2018;10(1):15. doi:10.1186/s13195-017-0314-2
- 35. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of
  Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of
  Health and Human Services Task Force on Alzheimer's Disease. *Neurology*. 1984;34(7):939-944.
- 944 doi:10.1212/wnl.34.7.939

- 36. Folstein MF, Folstein SE, McHugh PR. Mini-mental state: A practical method for grading the state of
  patients for the clinician. *Journal of Psychiatric Research*. 1975;12(3):189-198. doi:10.1016/00223956%2875%2990026-6
- 37. Wolfsgruber S, Kleineidam L, Guski J, et al. Minor neuropsychological deficits in patients with
  subjective cognitive decline. *Neurology*. 2020;95(9):e1134-e1143.

950 doi:10.1212/WNL.000000000010142

- 38. Wellcome Trust Centre for Human Neuroimaging, University College London. Statistical Parametric
   Mapping software. Accessed February 8, 2022. https://www.fil.ion.ucl.ac.uk/spm/
- 39. Structural Brain Mapping group, Jena University Hospital. CAT-Toolbox. Accessed February 8, 2022.
   http://www.neuro.uni-jena.de/cat/
- 40. Rajapakse JC, Giedd JN, Rapoport JL. Statistical approach to segmentation of single-channel cerebral
   MR images. *IEEE Trans Med Imaging*. 1997;16(2):176-186. doi:10.1109/42.563663
- 41. Ashburner J, Friston KJ. Diffeomorphic registration using geodesic shooting and Gauss-Newton
  optimisation. *Neuroimage*. 2011;55(3):954-967. doi:10.1016/j.neuroimage.2010.12.049
- 42. Laboratory for Computational Neuroimaging, Massachusetts General Hospital. Freesurfer. Accessed
   February 8, 2022. http://surfer.nmr.mgh.harvard.edu/
- 43. Fischl B, van der Kouwe A, Destrieux C, et al. Automatically parcellating the human cerebral cortex.
   *Cereb Cortex*. 2004;14(1):11-22. doi:10.1093/cercor/bhg087
- 44. Fischl B, Salat DH, Busa E, et al. Whole Brain Segmentation. *Neuron*. 2002;33(3):341-355.
   doi:10.1016/s0896-6273(02)00569-x
- 965 45. Busatto GF, Diniz BS, Zanetti MV. Voxel-based morphometry in Alzheimer's disease. *Expert Rev* 966 *Neurother*. 2008;8(11):1691-1702. doi:10.1586/14737175.8.11.1691
- 967 46. Ferreira LK, Diniz BS, Forlenza OV, Busatto GF, Zanetti MV. Neurostructural predictors of Alzheimer's
  968 disease: a meta-analysis of VBM studies. *Neurobiol Aging*. 2011;32(10):1733-1741.
  969 doi:10.1016/j.neurobiolaging.2009.11.008
- 47. Leandrou S, Petroudi S, Kyriacou PA, Reyes-Aldasoro CC, Pattichis CS. Quantitative MRI Brain Studies
  in Mild Cognitive Impairment and Alzheimer's Disease: A Methodological Review. *IEEE Rev Biomed Eng.* 2018;11:97-111. doi:10.1109/RBME.2018.2796598
- 48. Teipel SJ, Meindl T, Grinberg L, Heinsen H, Hampel H. Novel MRI techniques in the assessment of
   dementia. *Eur J Nucl Med Mol Imaging*. 2008;35 Suppl 1:S58-69. doi:10.1007/s00259-007-0703-z
- 49. Baker SL, Maass A, Jagust WJ. Considerations and code for partial volume correcting 18F-AV-1451
  tau PET data. *Data Brief*. 2017;(15):648-657. doi:10.1016/j.dib.2017.10.024
- 977 50. Iglesias JE, Augustinack JC, Nguyen K, et al. A computational atlas of the hippocampal formation
  978 using ex vivo, ultra-high resolution MRI: Application to adaptive segmentation of in vivo MRI.
  979 *Neuroimage*. 2015;115:117-137. doi:10.1016/j.neuroimage.2015.04.042
- 51. Koncz R, Sachdev PS. Are the brain's vascular and Alzheimer pathologies additive or interactive? *Curr Opin Psychiatry*. 2018;31(2):147-152. doi:10.1097/YCO.0000000000395
- 982 52. Roseborough A, Ramirez J, Black SE, Edwards JD. Associations between amyloid β and white matter
   983 hyperintensities: A systematic review. *Alzheimers Dement*. 2017;13(10):1154-1167.
   984 doi:10.1016/j.jalz.2017.01.026
- 53. Toledo JB, Arnold SE, Raible K, et al. Contribution of cerebrovascular disease in autopsy confirmed
   neurodegenerative disease cases in the National Alzheimer's Coordinating Centre. *Brain*.
   2013;136(Pt 9):2697-2706. doi:10.1093/brain/awt188
- 988 54. Mortamais M, Artero S, Ritchie K. Cerebral white matter hyperintensities in the prediction of
  989 cognitive decline and incident dementia. *Int Rev Psychiatry*. 2013;25(6):686-698.
  990 doi:10.3109/09540261.2013.838151
- 55. Schmidt P. Bayesian Inference for Structured Additive Regression Models for Large-Scale Problems
  with Applications Tomedical Imaging: Dissertation an Der Fakultät Für Mathematik, Informatik Und

993		Statistik Der Ludwig-Maximilians-Universität München. [Dissertation]: Ludwig-Maximilians-
994		Universität Munchen; 2017. http://nbn-resolving.de/urn:nbn:de:bvb:19-203731
995	56.	Schmidt P. LST. A lesion segmentation tool for SPM. Accessed March 7, 2022. http://www.statistical-
996		modelling.de/lst.html
997	57.	Bertens D, Tijms BM, Scheltens P, Teunissen CE, Visser PJ. Unbiased estimates of cerebrospinal fluid
998		β-amyloid 1-42 cutoffs in a large memory clinic population. <i>Alzheimers Res Ther</i> . 2017;9(1):8.
999		doi:10.1186/s13195-016-0233-7
1000	58.	Schwarz G. Estimating the Dimension of a Model. Ann Statist. 1978;6(2).
1001		doi:10.1214/aos/11/6344136
1002	59.	Hwang J, Jeong JH, Yoon SJ, et al. Clinical and Biomarker Characteristics According to Clinical
1003		Spectrum of Alzheimer's Disease (AD) in the Validation Cohort of Korean Brain Aging Study for the
1004		Early Diagnosis and Prediction of AD. J Clin Med. 2019;8(3). doi:10.3390/jcm8030341
1005	60.	Burnham SC, Coloma PM, Li Q-X, et al. Application of the NIA-AA Research Framework: Towards a
1006		Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study. J
1007		Prev Alzheimers Dis. 2019;6(4):248-255. doi:10.14283/jpad.2019.25
1008	61.	Grøntvedt GR, Lauridsen C, Berge G, et al. The Amyloid, Tau, and Neurodegeneration (A/T/N)
1009		Classification Applied to a Clinical Research Cohort with Long-Term Follow-Up. J Alzheimers Dis.
1010		2020;74(3):829-837. doi:10.3233/JAD-191227
1011	62.	Kakeda S, Korogi Y. The efficacy of a voxel-based morphometry on the analysis of imaging in
1012		schizophrenia, temporal lobe epilepsy, and Alzheimer's disease/mild cognitive impairment: a review.
1013		Neuroradiology. 2010;52(8):711-721. doi:10.1007/s00234-010-0717-2
1014	63.	Karas GB, Scheltens P, Rombouts SARB, et al. Global and local gray matter loss in mild cognitive
1015		impairment and Alzheimer's disease. <i>Neuroimage</i> . 2004;23(2):708-716.
1016		doi:10.1016/j.neuroimage.2004.07.006
1017	64.	Chételat G, Landeau B, Eustache F, et al. Using voxel-based morphometry to map the structural
1018		changes associated with rapid conversion in MCI: a longitudinal MRI study. <i>Neuroimage</i> .
1019		2005;27(4):934-946. doi:10.1016/j.neuroimage.2005.05.015
1020	65.	Pini L, Pievani M, Bocchetta M, et al. Brain atrophy in Alzheimer's Disease and aging. Ageing Res Rev.
1021		2016;30:25-48. doi:10.1016/j.arr.2016.01.002
1022	66.	Baron JC, Chételat G, Desgranges B, et al. In vivo mapping of gray matter loss with voxel-based
1023		morphometry in mild Alzheimer's disease. <i>Neuroimage</i> . 2001;14(2):298-309.
1024		doi:10.1006/nimg.2001.0848
1025	67.	Ramos Bernardes da Silva Filho S, Oliveira Barbosa JH, Rondinoni C, et al. Neuro-degeneration profile
1026		of Alzheimer's patients: A brain morphometry study. Neuroimage Clin. 2017;15:15-24.
1027		doi:10.1016/j.nicl.2017.04.001
1028	68.	Zanchi D, Giannakopoulos P, Borgwardt S, Rodriguez C, Haller S. Hippocampal and Amygdala Gray
1029		Matter Loss in Elderly Controls with Subtle Cognitive Decline. Front Aging Neurosci. 2017;9:50.
1030		doi:10.3389/fnagi.2017.00050
1031	69.	Jones BF, Barnes J, Uylings HBM, et al. Differential regional atrophy of the cingulate gyrus in
1032		Alzheimer disease: a volumetric MRI study. Cereb Cortex. 2006;16(12):1701-1708.
1033		doi:10.1093/cercor/bhj105
1034	70.	Kumar D, Ganeshpurkar A, Kumar D, Modi G, Gupta SK, Singh SK. Secretase inhibitors for the
1035		treatment of Alzheimer's disease: Long road ahead. Eur J Med Chem. 2018;148:436-452.
1036		doi:10.1016/j.ejmech.2018.02.035
1037	71.	van Dyck CH. Anti-Amyloid- $\beta$ Monoclonal Antibodies for Alzheimer's Disease: Pitfalls and Promise.
1038		Biol Psychiatry. 2018;83(4):311-319. doi:10.1016/j.biopsych.2017.08.010

- 1039 72. Masliah E, Mallory M, Hansen L, Richard D, Alford M, Terry R. Synaptic and neuritic alterations
  1040 during the progression of Alzheimer's disease. *Neuroscience Letters*. 1994;174(1):67-72.
  1041 doi:10.1016/0304-3940(94)90121-X
- 1042 73. Knowles RB, Gomez-Isla T, Hyman BT. Abeta associated neuropil changes: correlation with neuronal
  1043 loss and dementia. *J Neuropathol Exp Neurol*. 1998;57(12):1122-1130. doi:10.1097/000050721044 199812000-00003
- 1045 74. Fortea J, Vilaplana E, Alcolea D, et al. Cerebrospinal fluid β-amyloid and phospho-tau biomarker
   1046 interactions affecting brain structure in preclinical Alzheimer disease. *Ann Neurol*. 2014;76(2):223 1047 230. doi:10.1002/ana.24186
- 1048 75. Montal V, Vilaplana E, Alcolea D, et al. Cortical microstructural changes along the Alzheimer's
  1049 disease continuum. *Alzheimer's & Dementia*. 2018;14(3):340-351. doi:10.1016/j.jalz.2017.09.013
- 1050 76. Stern Y, Arenaza-Urquijo EM, Bartrés-Faz D, et al. Whitepaper: Defining and investigating cognitive
  1051 reserve, brain reserve, and brain maintenance. *Alzheimer's & Dementia*. 2020;16(9):1305-1311.
  1052 doi:10.1016/j.jalz.2018.07.219
- 1053 77. Ingala S, Boer C de, Masselink LA, et al. Application of the ATN classification scheme in a population
  1054 without dementia: Findings from the EPAD cohort. *Alzheimer's & Dementia*. 2021;17(7):1189-1204.
  1055 doi:10.1002/alz.12292
- 78. Nelson PT, Abner EL, Patel E, et al. The Amygdala as a Locus of Pathologic Misfolding in
   Neurodegenerative Diseases. *J Neuropathol Exp Neurol*. 2018;77(1):2-20. doi:10.1093/jnen/nlx099
- 1058 79. Mattsson-Carlgren N, Leuzy A, Janelidze S, et al. The implications of different approaches to define
   1059 AT(N) in Alzheimer disease. *Neurology*. 2020;94(21):e2233-e2244.
- 1060 doi:10.1212/WNL.00000000009485
- 1061 80. Illán-Gala I, Pegueroles J, Montal V, et al. Challenges associated with biomarker-based classification
   1062 systems for Alzheimer's disease. *Alzheimers Dement (Amst)*. 2018;10:346-357.
- 1063 doi:10.1016/j.dadm.2018.03.004
- 1064